Compositions and methods for administration of an enzyme to a subject's airway

Patent metadata

Field	Value
Publication number	US-11033611-B2
Application number	US-201916259112-A
Country	US
Kind code	B2
Filing date	Jan 28, 2019
Priority date	Nov 4, 2013
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI).

First claim

What is claimed is:

1. A method for treating a subject having a lung infection or lung injury, comprising administering to the lungs of the subject an amount of a composition comprising a plasminogen activator and a perfluorocarbon that is effective to treat the lung infection or lung injury.

2. The method of claim 1 , wherein the subject has chemical-induced lung injury.

3. The method of claim 2 , wherein the subject has plastic bronchitis, acute respiratory distress syndrome (ARDS) or inhalational smoke induced acute lung injury (ISALI).

4. The method of claim 1 , wherein the subject has a lung infection.

5. The method of claim 1 , further comprising delivering the composition to the lungs of the subject as a nebulized composition.

6. The method of claim 1 , wherein the plasminogen activator is a single chain urokinase plasminogen activator (scuPA) or a tissue plasminogen activator (tPA).

7. The method of claim 6 , wherein the plasminogen activator is a scuPA.

8. The method of claim 1 , wherein the perfluorocarbon comprises a cycloalkyl group.

9. The method of claim 1 , wherein the perfluorocarbon is selected from perfluorodecalin and perfluoro-octylbromide.

10. The method of claim 1 , wherein the perfluorocarbon comprises perfluorodecalin.

11. A method of treating inhalational smoke induced acute lung injury (ISALI) in a subject comprising administering to the lungs of the subject a therapeutically effective amount of a composition comprising a plasminogen activator and a perfluorocarbon.

12. The method of claim 11 , wherein the plasminogen activator is a single chain urokinase plasminogen activator (scuPA) or a tissue plasminogen activator (tPA).

13. The method of claim 11 , wherein the plasminogen activator is a scuPA.

14. The method of claim 11 , wherein the perfluorocarbon is selected from perfluorodecalin and perfluoro-octylbromide.

15. The method of claim 14 , wherein the perfluorocarbon comprises perfluorodecalin.

Assignees

• Univ Texas

Inventors

• Williams Iii Robert O
• Idell Steven

Classifications

• A61K9/0078 Primary

  for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title

• A61K38/49 Primary

  Urokinase; Tissue plasminogen activator · CPC title

• C12Y304/21073

  u-Plasminogen activator (3.4.21.73), i.e. urokinase · CPC title

• C12Y304/21068

  Tissue plasminogen activator (3.4.21.68), i.e. tPA · CPC title

• A61P11/06

  Antiasthmatics · CPC title